Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/2208461
Esophageal Reflux Partnering 2007-2012
Description:
The Esophageal Reflux Partnering 2007-2012 report provides understanding and access to the esophageal reflux partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in esophageal reflux partnering deals
- Top esophageal reflux deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
The Esophageal Reflux Partnering 2007-2012 provides understanding and access to the esophageal reflux partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of esophageal reflux partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors esophageal reflux technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 20 links to online copies of actual esophageal reflux deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of esophageal reflux partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in esophageal reflux partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading esophageal reflux deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of esophageal reflux partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of esophageal reflux technologies and products.
Report scope
Esophageal Reflux Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to esophageal reflux trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in esophageal reflux dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- Access to over 100 esophageal reflux contract documents
- The leading esophageal reflux deals by value since 2007
In Esophageal Reflux Partnering 2007-2012, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Benefits
Esophageal Reflux Partnering 2007-2012 provides the reader with the following key benefits:
- In-depth understanding of esophageal reflux deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 20 actual esophageal reflux deals entered into by the world’s biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
- Trends in esophageal reflux partnering deals
- Top esophageal reflux deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
The Esophageal Reflux Partnering 2007-2012 provides understanding and access to the esophageal reflux partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of esophageal reflux partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors esophageal reflux technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 20 links to online copies of actual esophageal reflux deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of esophageal reflux partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in esophageal reflux partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading esophageal reflux deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of esophageal reflux partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of esophageal reflux technologies and products.
Report scope
Esophageal Reflux Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to esophageal reflux trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in esophageal reflux dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- Access to over 100 esophageal reflux contract documents
- The leading esophageal reflux deals by value since 2007
In Esophageal Reflux Partnering 2007-2012, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Benefits
Esophageal Reflux Partnering 2007-2012 provides the reader with the following key benefits:
- In-depth understanding of esophageal reflux deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 20 actual esophageal reflux deals entered into by the world’s biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Contents:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in esophageal reflux partnering
- 2.1. Introduction
- 2.2. Esophageal reflux partnering over the years
- 2.3. Bigpharma esophageal reflux dealmaking activity
- 2.4. Esophageal reflux partnering by deal type
- 2.5. Esophageal reflux partnering industry sector
- 2.6. Esophageal reflux partnering by stage of development
- 2.7. Esophageal reflux partnering by technology type
- 2.8. Disclosed financial deal terms for esophageal reflux partnering
- 2.8.1 Esophageal reflux headline values
- 2.8.2 Esophageal reflux upfront payments
- 2.8.3 Esophageal reflux milestone payments
- 2.8.4 Esophageal reflux royalty rates
Chapter 3 – Leading esophageal reflux deals
- 3.1. Introduction
- 3.2. Top esophageal reflux deals by value
- 3.3. Top esophageal reflux deals involving bigpharma
Chapter 4 – Dealmaking directory
- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines
Chapter 5 – Partnering resource center
- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking
Appendices
- Appendix 1 – Deal type definitions
About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form – Reports
Table of figures
- Figure 1: esophageal reflux partnering since 2007
- Figure 2: Bigpharma – top 50 – esophageal reflux deals 2007 to 2011
- Figure 3: Bigpharma esophageal reflux deal frequency – 2007 to 2011
- Figure 4: Esophageal reflux partnering by deal type since 2007
- Figure 5: Esophageal reflux partnering by industry sector since 2007
- Figure 6: Esophageal reflux partnering by stage of development since 2007
- Figure 7: Esophageal reflux partnering by technology type since 2007
- Figure 8: Esophageal reflux deals with a headline value
- Figure 9: Esophageal reflux deals with upfront payment values
- Figure 10: Esophageal reflux deals with milestone payments
- Figure 11: Esophageal reflux deals with royalty rates, %
- Figure 12: Top esophageal reflux deals by value since 2007
- Figure 13: Top esophageal reflux deals signed by bigpharma value since 2007
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions
Chapter 1 – Introduction
Chapter 2 – Trends in esophageal reflux partnering
- 2.1. Introduction
- 2.2. Esophageal reflux partnering over the years
- 2.3. Bigpharma esophageal reflux dealmaking activity
- 2.4. Esophageal reflux partnering by deal type
- 2.5. Esophageal reflux partnering industry sector
- 2.6. Esophageal reflux partnering by stage of development
- 2.7. Esophageal reflux partnering by technology type
- 2.8. Disclosed financial deal terms for esophageal reflux partnering
- 2.8.1 Esophageal reflux headline values
- 2.8.2 Esophageal reflux upfront payments
- 2.8.3 Esophageal reflux milestone payments
- 2.8.4 Esophageal reflux royalty rates
Chapter 3 – Leading esophageal reflux deals
- 3.1. Introduction
- 3.2. Top esophageal reflux deals by value
- 3.3. Top esophageal reflux deals involving bigpharma
Chapter 4 – Dealmaking directory
- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines
Chapter 5 – Partnering resource center
- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking
Appendices
- Appendix 1 – Deal type definitions
About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form – Reports
Table of figures
- Figure 1: esophageal reflux partnering since 2007
- Figure 2: Bigpharma – top 50 – esophageal reflux deals 2007 to 2011
- Figure 3: Bigpharma esophageal reflux deal frequency – 2007 to 2011
- Figure 4: Esophageal reflux partnering by deal type since 2007
- Figure 5: Esophageal reflux partnering by industry sector since 2007
- Figure 6: Esophageal reflux partnering by stage of development since 2007
- Figure 7: Esophageal reflux partnering by technology type since 2007
- Figure 8: Esophageal reflux deals with a headline value
- Figure 9: Esophageal reflux deals with upfront payment values
- Figure 10: Esophageal reflux deals with milestone payments
- Figure 11: Esophageal reflux deals with royalty rates, %
- Figure 12: Top esophageal reflux deals by value since 2007
- Figure 13: Top esophageal reflux deals signed by bigpharma value since 2007
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions
Contents:
The Esophageal Reflux Partnering 2007-2012 report provides understanding and access to the esophageal reflux partnering deals and agreements entered into by the worlds leading healthcare companies.
On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.
The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service
On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.
The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Friday, May 24, 2013
9:32:16 AM
9:32:16 AM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Esophageal Reflux Partnering 2007-2012
Web Address
http://www.researchandmarkets.com/reports/2208461
Office Code
OC8DIQSNPSRTSV
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | CD ROM - Single User |
|
EURO€ 1,149.00 + EUR€ 50.00 Shipping/Handling * |
|---|---|---|
| Electronic (PDF) - Single User |
|
EURO€ 765.00 |
| Electronic (PDF) - 1 - 5 Users |
|
EURO€ 1,149.00 |
| Electronic (PDF) - Site License |
|
EURO€ 2,302.00 |
| Electronic (PDF) - Enterprisewide |
|
EURO€ 3,824.00 |
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Friday, May 24, 2013
9:32:16 AM
9:32:16 AM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp